Antibacterial activity of HRE 664, a new parenteral penem | Zendy

W. Cullmann | Zendy; M. Stieglitz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antibacterial activity of HRE 664, a new parenteral penem

Author(s) -

W. Cullmann,

M. Stieglitz

Publication year - 1988

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.32.7.1090

Subject(s) - aztreonam , imipenem , microbiology and biotechnology , piperacillin , staphylococcus aureus , ceftazidime , haemophilus influenzae , antibacterial agent , ampicillin , enterobacteriaceae , biology , acinetobacter , antibiotics , bacteria , escherichia coli , pseudomonas aeruginosa , antibiotic resistance , biochemistry , genetics , gene

The antibacterial activity of the new penem compound HRE 664 was evaluated in 451 clinical isolates, including ampicillin-resistant members of the family Enterobacteriaceae, Acinetobacter spp., Haemophilus influenzae, Staphylococcus aureus, and beta-hemolytic streptococci, and compared with those of piperacillin, ceftazidime, ceftriaxone, aztreonam, imipenem, and the penem compound Sch 34343. The new agent HRE 664 exhibited antibacterial activity comparable to that of the penem Sch 34343 and imipenem. The MICs of the new agent HRE 664 for 90% of the strains tested ranged from 1 to 4 micrograms/ml against Enterobacteriaceae and were 0.06 micrograms/ml for Staphylococcus aureus and 0.125 micrograms/ml for beta-hemolytic streptococci.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research